Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
History of Novartis, (trade)
One of the world's leading pharmaceutical companies, the Swiss multinational Novartis traces its history and that of its predecessor companies back to the first dye factories in Basel in the early 19th century.This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War and then the emergence of pharmaceuticals in the interwar years. The enormous challenges of the Second World War were followed by an economic boom in the 1950s and 60s, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and finally the first 25 years of Novartis. Those 25 years have included innovations in pharmaceuticals and medicine, and game-changing technologies such as the modification of T-cells.In addition to the running text, fifteen thematic articles outline the company's widely different innovations: from CIBA's early hormone preparations to the outstanding graphic design of Geigy Design, from revolutionary drugs like Sandimmune or Gleevec right through to the Novartis Campus project.
Novartis
The Swiss pharmaceutical industry is world-famous, and of today's top five global pharmaceutical businesses, two are Swiss - Roche and Novartis. Novartis was created in 1996 from a merger between three other major companies, Ciba, Geigy and Sandoz (the merger was the biggest ever in business history worldwide up to that point), but despite being a relatively new name, it is rooted in over 150 years of history. Focusing on the emergence of Novartis, this authoritative book is also the fascinating story of how Switzerland's pharmaceutical industry grew out of early dye-production for textiles in the mid nineteenth century, scored major triumphs with the introduction of products such as DDT and Valium in the twentieth century, and developed into the far-reaching international healthcare providers of today.
Novartis – an internal scanning of a pharmaceutical company
Research Paper (undergraduate) from the year 2004 in the subject Business economics - Business Management, Corporate Governance, grade: Distinction, University of East London, language: English, abstract: There is great value in reviewing the road an organization has travelled to get it to the place it is today. Accordingly, the process of identifying where you have been is both a qualitative and quantitative process. This study will analyse the background of the company and determine in detail the internal resources.
Cell and Gene Therapies
In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.
Clariant Clareant
Only those who are sure of their origin can know their destination. True to this principle, Anna Bálint for the first time presents the history of Clariant, the globally operating chemical company which was formed by a merger of Sandoz and Hoechst. Eyewitness accounts complete the portrait and give an informative as well as entertaining insight into the demanding task of successfully melding two distinct corporate cultures into a single strong and innovative enterprise.
Pharmaceutical Lifecycle Management
A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can—and must—do to get the most out of their brands. Offering a truly immersive introduction to LCM options for pharma...
HPLC for Pharmaceutical Scientists
HPLC for Pharmaceutical Scientists is an excellent book for both novice and experienced pharmaceutical chemists who regularly use HPLC as an analytical tool to solve challenging problems in the pharmaceutical industry. It provides a unified approach to HPLC with an equal and balanced treatment of the theory and practice of HPLC in the pharmaceutical industry. In-depth discussion of retention processes, modern HPLC separation theory, properties of stationary phases and columns are well blended with the practical aspects of fast and effective method development and method validation. Practical and pragmatic approaches and actual examples of effective development of selective and rugged HPLC methods from a physico-chemical point of view are provided. This book elucidates the role of HPLC throughout the entire drug development process from drug candidate inception to marketed drug product and gives detailed specifics of HPLC application in each stage of drug development. The latest advancements and trends in hyphenated and specialized HPLC techniques (LC-MS, LC-NMR, Preparative HPLC, High temperature HPLC, high pressure liquid chromatography) are also discussed.
Sharing Clinical Research Data
Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organi...
Transforming Clinical Research in the United States
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The...
CIO
None
